Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily

Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):396-398. doi: 10.1016/j.numecd.2020.09.028. Epub 2020 Oct 1.

Abstract

Background and aims: Diabetes mellitus (DM) has been associated with higher incidence of severe cases of COVID-19 in hospitalized patients, but it is unknown whether DM is a risk factor for the overall COVID-19 incidence. The aim of present study was to investigate whether there is an association of DM with COVID-19 prevalence and case fatality, and between different DM medications and risk for COVID-19 infection and death.

Methods and results: retrospective observational study on all SARS-CoV-2 positive (SARS-CoV-2+) cases and deaths in Sicily up to 2020, May 14th. No difference in COVID-19 prevalence was found between people with and without DM (RR 0.92 [0.79-1.09]). Case fatality was significantly higher in SARS-CoV-2+ with DM (RR 4.5 [3.55-5.71]). No diabetes medication was associated with differences in risk for SARS-Cov2 infection.

Conclusions: in Sicily, DM was not a risk factor for COVID-19 infection, whereas it was associated with a higher case fatality.

Keywords: COVID-19 case fatality; COVID-19 incidence; Diabetes mellitus.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 / epidemiology*
  • COVID-19 / mortality
  • Child
  • Child, Preschool
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / epidemiology*
  • Female
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Incidence
  • Infant
  • Male
  • Middle Aged
  • Prevalence
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2
  • Sicily / epidemiology
  • Young Adult

Substances

  • Hypoglycemic Agents